DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar

Today's Daily Dose brings you news about FDA approval of AbbVie's new hepatitis C drug; ARCA biopharma's anticipated milestones; the delay in approval of Dynavax's experimental hepatitis B vaccine; the approval of the first new chemotherapy advance in the U.S. in more than 40 years for adults with certain types of AML, and the clinical trial catalysts to watch out for in Otonomy.

from RTT - Biotech http://ift.tt/2vysXew
via IFTTT